secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001746473-25-000182
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Pliant Therapeutics promotes Minnie Kuo to COO effective December 10, 2025
--------------------------------------------------------------------------

- Minnie Kuo appointed Chief Operating Officer, effective immediately; previously served as Chief Development Officer since September 2023.
- Ms. Kuo has over 20 years of multinational clinical development experience, including senior roles at Vir Biotechnology, Gilead Sciences, and Roche/Genentech.
- No additional compensation provided with the COO appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000182/0001746473-25-000182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000174647325000182/plrx-20251210.htm
  HTML page:      https://secwatch.observer/filing/0001746473-25-000182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer